The Biochemical Pharmacology Discussion Group is proudly supported by:
Lead Supporters
![]() | ![]() |
Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.
DONATEAvailable via
WEBINAR
Tuesday, April 17, 2018, 9:00 AM - 6:00 PM EDT
The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York
Fibrosis is a common pathology in many chronic diseases and is often associated with disease progression. Many extracellular matrix macromolecules, as well as their regulators and modifiers have been identified as potential disease targets or biomarkers by extensive studies in numerous preclinical animal models of fibrosis. However, therapeutics development depends on in vitro experimental systems that model pathological processes in order to build assays for screening, mechanistic characterization and target disease link evaluation. In vitro fibrosis experimental systems have been limited, but a better understanding of shared pathways and the distinctions that lead to fibrosis in different organs is now emerging from technical advances such as proteomics, RNAseq, laser capture microdissection and the availability of clinical materials. The advent of engineered substrata with defined biomechanical properties, the use of stem cells and capabilities for genetic modification have also contributed to the design of increasingly sophisticated in vitro models of fibrosis. When coupled with co-culture and organoid technologies, these advances enable modeling of cell and tissue interactions in normal and fibrotic settings. This symposium will review what is known about the cell and molecular biology of fibrosis and reparative healing, discuss current model systems, and consider the challenges and opportunities for future innovation.
![]() | ![]() |
April 17, 2018
Speakers
Speaker
Speaker
Speaker
Speaker
Speaker
Speaker
Speaker
Speaker
Speaker
Speaker
Speaker
Speaker
Speaker